GRIA1 and epilepsy: Also, in this case, the CSF, the serum, or some purified human anti-GluA antibodies from patients suffering from central anti-AMPA autoimmune pathologies (i.e., Rasmussen encephalitis; epilepsy; FTD), as well as purified anti-GluA antibodies isolated from animals immunized with selected GluA aminoacidic sequences (i.e., GluA1, 2, and 3 subunits; [98,99]), were tested in in vitro and ex vivo neuronal models (i.e., HEK cells, cultured neurons, isolated nerve terminals, brain slices) to evaluate changes in the AMPA receptor distribution and functions [98,100,101,102,103,104,105].